For hospital pharmacy directors at ENT (ear, nose, throat) departments, primary care physicians treating patients with acute and chronic pharyngitis and tonsillitis, and procurement managers at community health clinics, a persistent clinical challenge remains: recurrent throat inflammation, pain, swelling, and difficulty swallowing affect millions of patients annually. Western treatments include antibiotics (for bacterial infections), NSAIDs (pain and inflammation), and lozenges (symptomatic relief). However, patients with chronic conditions or those preferring traditional medicine seek alternative options with anti-inflammatory, detoxifying, and cooling properties. Qing Hou Yan He Ji directly addresses this need as a Chinese patent medicine made from multiple Chinese medicinal materials, formulated with the effects of clearing away heat and detoxification, moistening the throat and relieving pain, and reducing swelling and dispersing nodules. According to the latest industry benchmark, the global market for Qing Hou Yan He Ji was valued at USD 37.2 million in 2024 and is forecast to reach a readjusted size of USD 50.3 million by 2031, growing at a modest compound annual growth rate (CAGR) of 3.7% during the forecast period 2025-2031. This stable growth reflects consistent demand for traditional Chinese medicine (TCM) throat remedies in China and among Chinese diaspora communities, driven by seasonal respiratory infections, air pollution-related throat irritation, and an aging population susceptible to chronic pharyngitis. *Global Leading Market Research Publisher QYResearch announces the release of its latest report "Qing Hou Yan He Ji - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Qing Hou Yan He Ji market, including market size, share, demand, industry development status, and forecasts for the next few years.* 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/4662302/qing-hou-yan-he-ji 1. Product Definition: Chinese Patent Medicine for Throat Diseases Qing Hou Yan He Ji (also known as "Throat Clearing Mixture" or "Pharyngitis Mixture") is a Chinese patent medicine (a TCM formulation manufactured under state-approved standards, similar to proprietary Chinese medicine). It is primarily used to treat throat diseases, including acute and chronic pharyngitis (inflammation of the pharynx), tonsillitis (inflammation of the tonsils), and laryngitis (inflammation of the larynx/vocal cords). The medicine is formulated from a variety of Chinese medicinal materials selected for their specific therapeutic properties: (1) clearing away heat and detoxification – reducing inflammation and eliminating pathogens (heat-clearing herbs such as Scutellaria baicalensis (Huang Qin), Forsythia suspensa (Lian Qiao), and Lonicera japonica (Jin Yin Hua), (2) moistening the throat and relieving pain – soothing irritated mucous membranes and reducing discomfort (herbs such as Platycodon grandiflorus (Jie Geng) and Ophiopogon japonicus (Mai Men Dong), (3) reducing swelling and dispersing nodules – addressing swollen tonsils, lymphoid follicles, and other inflammatory nodules (herbs such as Prunella vulgaris (Xia Ku Cao) and Curcuma longa (Jiang Huang). The product is presented as an oral liquid mixture (He Ji), typically packaged in tubes or bottles with measured dosing. Two primary bottle/tube sizes (segment by type – QYResearch classification): Each Tube Contains 15ml – Larger size, suitable for extended treatment courses (typically 5-7 days). Better value per ml. Estimated larger volume segment. Each Tube Contains 10ml – Smaller size, suitable for short-course treatment (3-5 days), pediatric dosing, or trial use. Lower upfront cost. End-user segments (segment by application): Hospital – Largest segment (~50-55% of revenue). Prescribed by TCM or ENT physicians in hospital settings. Dispensed through hospital pharmacies. Clinic – Significant segment (~30-35%). Community health clinics, TCM clinics, outpatient ENT clinics. Prescription or OTC with TCM practitioner recommendation. Other – Retail TCM pharmacies, online TCM shops, nursing homes, schools (flu season stockpiling) (~15-20%). 2. Industry Development Trends: China-Centric Market, Fragmented Manufacturing, and Seasonal Demand Based on analysis of corporate annual reports (limited, as most manufacturers are Chinese TCM companies), Chinese pharmaceutical market trends, and industry news from Q4 2025 to Q2 2026, four dominant trends shape the Qing Hou Yan He Ji sector: 2.1 China-Centric Market with Limited Global Presence The Qing Hou Yan He Ji market is almost entirely contained within China. All 20+ manufacturers identified are Chinese pharmaceutical companies. The product is not widely approved or marketed outside China (no FDA, EMA, or PMDA approvals), though it may be available in Chinese diaspora communities via TCM shops. The market size (USD 37.2 million in 2024) reflects a mature, regionally confined TCM patent medicine. Growth is driven by China's healthcare spending, seasonal respiratory infections, air pollution-related throat irritation (particulate matter PM2.5 and PM10), an aging population (chronic pharyngitis prevalence increases with age), and persistent demand for TCM alternatives to Western pharmaceuticals. 2.2 Highly Fragmented Manufacturing Landscape with Regional Players The market is highly fragmented, with 20+ manufacturers identified, all Chinese regional pharmaceutical companies. Key players include: Hunan Times Sunshine Pharmaceutical Co., Ltd., China Resources Sanjiu (Zaozhuang) Pharmaceutical Co., Ltd. (subsidiary of China Resources, a state-owned conglomerate), Anguo Yadong Biopharmaceutical Co., Ltd., Chengdu Beitedenuo Pharmaceutical Co., Ltd., Guangzhou Baiyunshan Xingqun (Pharmaceutical) Co., Ltd. (part of Guangzhou Baiyunshan, major TCM group), Jilin Sanjiu Jinfukang Pharmaceutical Co., Ltd., Guangxi Yulin Fangte Pharmaceutical Co., Ltd., Jiangxi Jimin Kexin Pharmaceutical Co., Ltd., Tianjin Children's Pharmaceutical Co., Ltd., Jiangxi Yaodu Zhangshu Pharmaceutical Co., Ltd., Shaanxi Huaxi Pharmaceutical Co., Ltd., Chengdu Dikang Pharmaceutical Co., Ltd., Henan Baiquan Pharmaceutical Co., Ltd., Henan Confidence Pharmaceutical Co., Ltd., Zhejiang Kangenbei Chinese Medicine Co., Ltd., Mudanjiang Lingtai Pharmaceutical Co., Ltd., Sanmenxia Guangyu Biopharmaceutical Co., Ltd., Hebei Kangzhi Pharmaceutical Co., Ltd., Shandong Yuecaotang Pharmaceutical Co., Ltd., Guangdong Huazhou Chinese Medicine Factory Pharmaceutical Co., Ltd. China Resources Sanjiu (subsidiary of a major state-owned enterprise) is the most significant corporate participant. The market is fragmented; no single player dominates. Low barriers to entry for TCM oral liquids contribute to fragmentation. 2.3 Seasonal Demand Driven by Respiratory Infections and Air Quality Demand for throat medications spikes during: (1) winter and early spring (peak respiratory infection seasons: influenza, RSV, common cold), (2) periods of poor air quality (high PM2.5 levels in northern China during winter inversions, sandstorms in spring). In China, seasonal patterns (December-February, July-August for summer respiratory infections) drive hospital and clinic procurement. Manufacturers adjust production accordingly. Air quality alerts (e.g., Beijing, Tianjin, Hebei "2+26" cities) correlate with increased pharmacy sales of throat remedies. 2.4 Competition from Other Throat Medications Qing Hou Yan He Ji competes with: (1) Western throat lozenges (e.g., Strepsils, Cepacol) – convenient, OTC, widely available, (2) antibiotics (for bacterial pharyngitis/tonsillitis) – prescription, curative but not indicated for viral pharyngitis, (3) other TCM throat patent medicines (e.g., Huang Sheng Yin, Qing Yan Li Hou Pian, Liu Shen Wan, Xi Gua Shuang) – direct competitors, (4) symptomatic sprays (e.g., throat sprays containing benzydamine, lidocaine) – rapid relief. Qing Hou Yan He Ji's differentiation is its TCM-based formula (heat-clearing, detoxifying), familiarity among TCM-prescribing physicians, and patient preference for "natural" ingredients. Industry Layering Perspective: Hospital vs. Clinic vs. Other Hospital – Largest segment. Prescription required. Dispensed by hospital pharmacies (TCM and ENT). Higher trust (patients believe hospital-dispensed products are safer and regulated). Higher price (includes hospital markup). Clinic – Significant segment. Community health clinics, TCM clinics. May be prescribed or recommended. Lower price (lower markup). Other – Retail TCM pharmacies, online TCM shops. Over-the-counter availability (though TCM practitioner consultation often recommended). Lowest price (no hospital/clinic markup), but higher risk of counterfeit products. 3. Market Segmentation and Competitive Landscape Segment by Bottle/Tube Size (Type): 15ml – Larger share (~55-60% of revenue). Extended treatment courses. 10ml – Moderate share (~40-45% of revenue). Shorter courses, pediatric, trial. Segment by End-User (Application): Hospital – Largest (~50-55% of revenue) Clinic – Significant (~30-35%) Other – Retail, online (~15-20%) Key Market Players (QYResearch-identified – representative list): The market is highly fragmented with 20+ manufacturers. The most significant corporate participant is China Resources Sanjiu (Zaozhuang) Pharmaceutical Co., Ltd. (subsidiary of China Resources, a state-owned conglomerate with extensive pharmaceutical distribution). Guangzhou Baiyunshan Xingqun (Pharmaceutical) Co., Ltd. (part of Guangzhou Baiyunshan, a major TCM group listed on Hong Kong and Shanghai stock exchanges) is another notable player. Jilin Sanjiu Jinfukang Pharmaceutical Co., Ltd. (likely affiliated with China Resources Sanjiu). Other players are regional. No single manufacturer dominates >10-15% market share. 4. Exclusive Expert Insights and Recent Developments (Q4 2025 – Q2 2026) Insight #1 – China's National Volume-Based Procurement (VBP) and TCM Products China's VBP program, which has significantly reduced prices for many generic Western drugs, has not yet extensively covered TCM patent medicines (including Qing Hou Yan He Ji). However, provincial-level centralized procurement negotiations occur. Estimated average hospital procurement price for Qing Hou Yan He Ji is USD 1.50-2.50 per 15ml tube (wholesale). Retail price to patient (after hospital markup and insurance) is USD 2.50-4.00. Margins are compressed but stable. VBP expansion to TCM products would further reduce prices, favoring larger manufacturers with economies of scale. Insight #2 – Post-COVID Awareness of Throat Health The COVID-19 pandemic (2020-2023) increased public awareness of respiratory and throat health. Pharyngitis and sore throat are common COVID-19 symptoms. Even post-pandemic, consumers are more attentive to throat discomfort, leading to sustained elevated demand for throat remedies (10-15% above pre-pandemic baseline). This trend supports the 3.7% CAGR. Insight #3 – Competition from "Herbal Candy" and Functional Foods Younger consumers (under 40) increasingly purchase functional "herbal candies" and lozenges containing TCM ingredients (e.g., herbal throat drops, sugar-free cooling lozenges) from convenience stores and online platforms. These products (e.g., Wanglaoji throat drops, various herbal hard candies) are not registered as pharmaceuticals, do not require prescriptions, and are marketed as "food supplements." They compete for the same consumer throat discomfort use case, especially for mild symptoms. This may limit growth for the pharmaceutical-grade Qing Hou Yan He Ji among younger demographics. Typical User Case (Q1 2026 – Community Health Clinic, Guangdong Province): A community health clinic in Guangdong Province treats a 35-year-old female patient with acute pharyngitis (sore throat, pain on swallowing, mild fever, redness of pharynx). Rapid strep test negative (viral etiology). The physician prescribes Qing Hou Yan He Ji (15ml tube, three times daily for 5 days) along with symptomatic rest and hydration. The clinic dispenses the product from its pharmacy (cost: USD 1.80 wholesale, patient co-pay USD 0.50 after basic medical insurance). After 3 days, the patient reports significant symptom improvement (pain reduced 70%). She completes the 5-day course without antibiotics. This case is typical: viral pharyngitis, patient prefers non-antibiotic treatment, TCM product prescribed as symptomatic therapy. 5. Technical Challenges and Future Pathways Despite steady demand, challenges persist for Qing Hou Yan He Ji market: Lack of rigorous clinical evidence (by Western standards) – While TCM has centuries of empirical use, modern evidence-based medicine requires randomized controlled trials (RCTs) demonstrating efficacy and safety. Few high-quality RCTs on Qing Hou Yan He Ji exist in international journals. This limits acceptance outside China and among younger, scientifically-literate Chinese consumers. Competition from convenient OTC Western products – Lozenges and sprays are more convenient (no bottle, no measuring), available at any pharmacy without prescription, and heavily advertised. Qing Hou Yan He Ji's oral liquid format requires measuring (using the provided cap or a spoon), which some patients find less convenient. Unit-dose packaging (pre-measured single-dose sachets) could improve convenience but increases manufacturing cost. Sugar content and taste acceptability – TCM oral liquids often contain sugar or sweeteners to mask bitterness of herbs. Diabetic patients may be advised to avoid sugary TCM products. Taste (bitter, medicinal) may deter some patients, especially children. Sugar-free versions exist but not universally. Future Direction: The Qing Hou Yan He Ji market will continue its 3-4% CAGR through 2031, driven by: (1) seasonal respiratory infections, (2) air pollution-related throat irritation, (3) aging population (chronic pharyngitis prevalence), (4) sustained demand for TCM alternatives. Key strategic imperatives for manufacturers: (1) invest in clinical research (RCTs) to strengthen evidence base, (2) develop unit-dose packaging for convenience, (3) expand distribution via TCM hospital formularies, (4) explore sugar-free formulations for diabetic patients. For hospital and clinic procurement managers, this product remains a familiar, culturally acceptable, and affordable option for viral pharyngitis and chronic throat conditions, though patients seeking rapid convenience may prefer lozenges or sprays. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp